Skip to content
Starsource Multitrade logo

Starsource Multitrade

506365 BSE
Price unavailable

Starsource Multitrade (STARSOURCE) share price was ₹108.65 at the 28 Oct 2026 close; market capitalisation ₹16.30 Cr; sector Healthcare. The share price fell 11.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹0.07 Cr, against under ₹0.01 Cr a year earlier and net profit was ₹0.02 Cr, against −₹11.81 Cr a year earlier (compared with Jun 2025). Promoters held 27.89% of Starsource Multitrade in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 38/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹108.65 −7.70 −6.62% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹16.30 Cr
EBITDA
−₹1.30 Cr
Return on Equity
-39.44%
Debt to Equity
0
Book Value
₹8.60
EPS (TTM)
−₹0.27
52W High
₹152.90
52W Low
₹70.01

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.8035.054,23,915 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,608.9072.351,75,308 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,188.50108.131,18,247 Cr22.310.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.7034.671,11,739 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Starsource Multitrade (this company)
——16 Cr12.630.00%-39.44%-35.52%1 Cr-0 Cr
Median 8 companies₹1,766.8035.051,18,066 Cr7.310.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

38 Weak
Overall score

Data confidence 77/100

Category scores

Quality Poor 29
Returns, margins, earnings quality 24% weight
Valuation Poor 17
Cheap vs sector & own history 26% weight
Financial Health Average 55
Solvency, leverage, coverage 10% weight
Momentum Average 54
Trend strength, vol-adjusted 13% weight
Ownership Average 50
FII/DII/promoter flows 26% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

5
  • Stock is trading at 12.3 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding is low: 27.9%
  • Company has a low return on equity of 5.09% over last 3 years.
  • Company has high debtors of 337 days.

Technical Indicators

Oscillators

Bullish

Bearish
0
Neutral
5
Bullish
4

Overall

Bullish

Bearish
1
Neutral
5
Bullish
13

Moving Averages

Bullish

Bearish
1
Neutral
0
Bullish
9

Growth Rate

Net Income Growth
100% higher than 3Y

change over 1 year

Cash Flow Change
-103%

change over 1 year

EBITDA Margin Change
—

Operating margin 28.57% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
0
0.53
0
0
0.07
Expenses
0.05
0.02
0.02
0.1
0.05
0.02
0.02
0.02
11.83
0.43
0.09
0.07
0.05
Operating Profit
-0.05
-0.02
-0.02
-0.1
-0.05
-0.02
-0.02
-0.02
-11.83
0.1
-0.09
-0.07
0.02
OPM %
—
—
—
—
—
—
—
—
—
18.87%
—
—
28.57%
Other Income
0.43
0.46
0.7
0.25
0.3
0.63
-0.15
-0.16
0.02
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.38
0.44
0.68
0.15
0.25
0.61
-0.17
-0.18
-11.81
0.1
-0.09
-0.07
0.02
Tax %
0%
0%
0%
293.33%
0%
0%
0%
88.89%
0%
0%
0%
0%
0%
Net Profit
0.38
0.44
0.68
-0.29
0.25
0.61
-0.17
-0.34
-11.81
0.1
-0.09
-0.07
0.02
EPS (₹)
2.53
2.93
4.53
-1.93
1.67
4.07
-1.13
-2.27
-78.73
0.67
-0.6
-0.47
0.13
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
0
0
0
0
0
0
0
0
0.53
0.6
Expenses
0.12
0.17
0.27
0.34
0.56
0.48
0.34
0.41
0.2
0.19
0.12
0.53
0.64
Operating Profit
-0.12
-0.17
-0.27
-0.34
-0.56
-0.48
-0.34
-0.41
-0.2
-0.19
-0.12
0
-0.04
OPM %
—
—
—
—
—
—
—
—
—
—
—
0%
-6.67%
Other Income
0.5
0.49
5.61
1.11
0.82
1
0.67
0.79
0.3
1.84
0.62
-11.85
0
Interest
0
0
0
0
0
0
0
0
0.01
0
0
0
0
Depreciation
0
0
0
0
0
0.02
0.02
0.02
0.01
0.01
0.01
0
0
PBT
0.38
0.32
5.34
0.77
0.26
0.5
0.31
0.36
0.08
1.64
0.49
-11.85
-0.04
Tax %
26.32%
31.25%
12.17%
85.71%
19.23%
16%
19.35%
-55.56%
37.5%
26.83%
32.65%
0%
—
Net Profit
0.28
0.22
4.68
0.1
0.21
0.42
0.25
0.56
0.05
1.2
0.34
-11.85
-0.04
EPS (₹)
1.87
1.47
31.2
0.67
1.4
2.8
1.67
3.73
0.33
8
2.27
-79
-0.27
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
Reserves
3.62
3.84
8.52
8.62
8.83
9.24
9.49
10.05
10.1
11.3
11.64
-0.21
Borrowings
0
0
0.12
0
0
0
0
0
0
0
0
0
Other Liabilities
0.46
0.2
0.58
0.13
0.09
0.22
0.06
0.11
0.02
0.21
0.21
0.53
Total Liabilities
5.58
5.54
10.72
10.25
10.42
10.96
11.05
11.66
11.62
13.01
13.35
1.82
Fixed Assets
0
0
0.01
0
0
0.07
0.05
0.04
0.03
0.02
0.01
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
1.68
1.68
0.02
0.02
0.04
0.02
0.04
2.94
3.03
4.4
0.01
0.01
Other Assets
3.9
3.86
10.69
10.23
10.38
10.87
10.96
8.68
8.56
8.59
13.33
1.81
Total Assets
5.58
5.54
10.72
10.25
10.42
10.96
11.05
11.66
11.62
13.01
13.35
1.82
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-0.05
-0.43
6.41
-1.66
-5.48
4.83
-0.41
-0.33
-0.68
0.72
-0.28
-10.62
Investing
0.25
0.49
0.52
1.08
0.79
1.01
-0.19
0.97
0.63
-0.52
10.46
0.01
Financing
0
0
-0.5
1.37
0
0
1.96
-2.12
-0.08
-0.15
-0.16
0
Net Cash Flow
0.2
0.06
6.43
0.79
-4.7
5.84
1.36
-1.49
-0.13
0.05
10.02
-10.61
Free Cash Flow
-0.05
-0.43
6.41
-1.66
-5.48
4.83
-0.41
-0.33
-0.68
0.72
-0.28
-10.62
CFO/EBITDA
-25
206
-2,615
294
970
-1,023
94
66
335
-468
67
—
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
—
—
—
—
—
—
—
—
337
Inventory Days
—
—
—
—
—
—
—
—
—
—
—
0
Cash Conversion Cycle
—
—
—
—
—
—
—
—
—
—
—
337
Working Capital Days
—
—
—
—
—
—
—
—
—
—
—
875
ROCE %
7.62%
6.12%
3.62%
7.6%
2.54%
4.75%
2.85%
1.33%
0.78%
13.28%
5.17%
0.28%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Starsource Multitrade insights

55 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs0.37%Public65.86%Others5.89%Promot.27.89%As ofSep 2026

Documents

Frequently Asked Questions about Starsource Multitrade

What does Starsource Multitrade Ltd do?
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
Where is Starsource Multitrade Ltd (STARSOURCE) listed?
Starsource Multitrade Ltd trades under code 506365 on the BSE.
Which sector does Starsource Multitrade Ltd belong to?
Starsource Multitrade Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Starsource Multitrade Ltd?
Starsource Multitrade Ltd has a market capitalisation of ₹16.3 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Starsource Multitrade Ltd?
Over the last 52 weeks Starsource Multitrade Ltd has traded between ₹70.01 and ₹152.9 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Starsource Multitrade Ltd?
Starsource Multitrade Ltd reported a return on equity of -39.44%. Its debt-to-equity ratio is 0.00.

Company Information

The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]

Website thechemopharmalaboratoriesltd.com
Face Value ₹ 10
Shares Outstanding 15,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506365.md for Starsource Multitrade Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month